Back to search results

Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy

This study is for adults experiencing pain from chemotherapy-induced peripheral neuropathy (CIPN), a condition causing pain, numbness, or tingling, often in the hands and feet, after cancer treatment. It's testing a device called Scrambler Therapy, which uses electrical signals to help manage pain. You could be eligible if you've had CIPN pain for at least three months, rate your pain as 4 out of 10 or higher, and haven't had certain cancer treatments recently. The study aims to see if Scrambler Therapy can reduce your pain, measured at the beginning and up to 14 days after treatment. This study is currently unclear on its recruitment status and plans to enroll 90 participants.

Study design
This study is designed to compare Scrambler Therapy to a sham (inactive) treatment. You would be blinded, meaning you wouldn't know if you're receiving the active or sham treatment.
What's involved
You would attend 10 daily 45-minute sessions, Monday through Friday, for two consecutive weeks. Your pain levels will be checked at the start of the study and again up to 14 days after your last treatment session.
Compensation
Not stated in the trial record.
Follow-up
Your pain will be measured at the end of treatment, up to 14 days later.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07219472

Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy

Recruiting
NAAges 18+InterventionalSupportive care
Case Comprehensive Cancer Center
~90 participants
Updated 2026-08-05 on ClinicalTrials.gov
What's tested:Scrambler TherapySham/No Intervention

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in participant-reported pain
Measured over Baseline, end of treatment (up to 14 days)

Conditions

Chemotherapy-induced Peripheral Neuropathy
CIPN - Chemotherapy-Induced Peripheral Neuropathy

Explore related trials

Chemotherapy-Induced Peripheral Neuropathy

Where it's being run

1 sites across 1 states
Ohio1

Study leadership

  • Laura Shoemaker, DO, MS, FAAHPM · PRINCIPAL_INVESTIGATOR · Case Comprehensive Cancer Center, Cleveland Clinic

Who to contact

Laura Shoemaker, DO, MS, FAAHPM
[email protected]
(216) 444-5193
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults with CIPN-related pain for at least three months duration, and for which the participant wants intervention
At least three months from the last dose of neurotoxic cancer-directed drug
No plan (at the time of study enrollment) for additional neurotoxic cancer-directed therapies for at least five months after trial enrollment
Pain rated ≥ four out of 10 in severity (0-10 pain scale) during the seven days prior to enrollment
\> Six-month life expectancy
Able to complete questionnaires by themselves or with assistance
Able to provide informed written consent
ECOG Performance Status score ≥ two
Not currently enrolled in another research study for pain or neuropathy

Exclusion

Pregnant or nursing
An operational implanted drug delivery system, implanted electronic medical device, life supporting medical device, and/or medical monitoring device
History of myocardial infarction or ischemic heart disease within six months of trial enrollment
History of epilepsy, brain damage resulting in seizure activity, or use of anticonvulsants for seizure
Skin conditions such as open sores that will prevent proper application of electrodes
Unwillingness or inability to wean and discontinue gabapentin or pregabalin prior to the start of ST
History of symptomatic peripheral neuropathy prior to receiving neurotoxic chemotherapy
Prior treatment with Scrambler Therapy
The presence of chronic regional pain syndrome (CRPS) in the scrambler therapy treatment area.

What this trial measures

  • Change in participant-reported painBaseline, end of treatment (up to 14 days)

    Participant-reported pain is measured by the Severity of Neuropathic Symptoms, in which participants rank their pain on a scale of 0 (Not at All) to 10 (Severe). Higher scores indicate greater pain symptoms.